FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Champoux Jennifer</u>						2. Issuer Name and Ticker or Trading Symbol Monte Rosa Therapeutics, Inc. [ GLUE ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner				
(Last) MONTE	•	irst) ERAPEUTICS,		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024								Officer (give title Other (specify below)  Chief Operating Officer						
321 HARRISON AVENUE, SUITE 900						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person				
(Street) BOSTO	,		02118												led by More	than One Repo		
(City) (State) (Zip)			(Zip)		R	Rule 10b5-1(c) Transaction Indication											440	
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins	ion   Di	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	/ Ai	Amount (A) or (D)		Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
		7	Table II -						ired, Dis					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	Code	v	(A)		Date Exercisable		iration	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$3.98	06/03/2024			A		40,000		(1)	06/03	3/2034	Common Stock	40,000	\$0	40,000	D		

## **Explanation of Responses:**

1. 25% of this option shall vest and become exercisable on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

/s/ Phil Nickson, Attorney-in-

Fact

\*\* Signature of Reporting Person

Date

06/05/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.